Evaluation of anti-HIV-1 mutagenic nucleoside analogues. 2015

Valérie Vivet-Boudou, and Catherine Isel, and Yazan El Safadi, and Redmond P Smyth, and Géraldine Laumond, and Christiane Moog, and Jean-Christophe Paillart, and Roland Marquet
From the Architecture et Réactivité de l'ARN, Université de Strasbourg, CNRS, IBMC, 67084 Strasbourg Cedex and v.vivet@ibmc-cnrs.unistra.fr.

Because of their high mutation rates, RNA viruses and retroviruses replicate close to the threshold of viability. Their existence as quasi-species has pioneered the concept of "lethal mutagenesis" that prompted us to synthesize pyrimidine nucleoside analogues with antiviral activity in cell culture consistent with an accumulation of deleterious mutations in the HIV-1 genome. However, testing all potentially mutagenic compounds in cell-based assays is tedious and costly. Here, we describe two simple in vitro biophysical/biochemical assays that allow prediction of the mutagenic potential of deoxyribonucleoside analogues. The first assay compares the thermal stabilities of matched and mismatched base pairs in DNA duplexes containing or not the nucleoside analogues as follows. A promising candidate should display a small destabilization of the matched base pair compared with the natural nucleoside and the smallest gap possible between the stabilities of the matched and mismatched base pairs. From this assay, we predicted that two of our compounds, 5-hydroxymethyl-2'-deoxyuridine and 5-hydroxymethyl-2'-deoxycytidine, should be mutagenic. The second in vitro reverse transcription assay assesses DNA synthesis opposite nucleoside analogues inserted into a template strand and subsequent extension of the newly synthesized base pairs. Once again, only 5-hydroxymethyl-2'-deoxyuridine and 5-hydroxymethyl-2'-deoxycytidine are predicted to be efficient mutagens. The predictive potential of our fast and easy first line screens was confirmed by detailed analysis of the mutation spectrum induced by the compounds in cell culture because only compounds 5-hydroxymethyl-2'-deoxyuridine and 5-hydroxymethyl-2'-deoxycytidine were found to increase the mutation frequency by 3.1- and 3.4-fold, respectively.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009153 Mutagens Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. Clastogen,Clastogens,Genotoxin,Genotoxins,Mutagen
D009691 Nucleic Acid Denaturation Disruption of the secondary structure of nucleic acids by heat, extreme pH or chemical treatment. Double strand DNA is "melted" by dissociation of the non-covalent hydrogen bonds and hydrophobic interactions. Denatured DNA appears to be a single-stranded flexible structure. The effects of denaturation on RNA are similar though less pronounced and largely reversible. DNA Denaturation,DNA Melting,RNA Denaturation,Acid Denaturation, Nucleic,Denaturation, DNA,Denaturation, Nucleic Acid,Denaturation, RNA,Nucleic Acid Denaturations
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D013816 Thermodynamics A rigorously mathematical analysis of energy relationships (heat, work, temperature, and equilibrium). It describes systems whose states are determined by thermal parameters, such as temperature, in addition to mechanical and electromagnetic parameters. (From Hawley's Condensed Chemical Dictionary, 12th ed) Thermodynamic
D013936 Thymidine A nucleoside in which THYMINE is linked to DEOXYRIBOSE. 2'-Deoxythymidine,Deoxythymidine,2' Deoxythymidine
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Valérie Vivet-Boudou, and Catherine Isel, and Yazan El Safadi, and Redmond P Smyth, and Géraldine Laumond, and Christiane Moog, and Jean-Christophe Paillart, and Roland Marquet
May 2015, ChemMedChem,
Valérie Vivet-Boudou, and Catherine Isel, and Yazan El Safadi, and Redmond P Smyth, and Géraldine Laumond, and Christiane Moog, and Jean-Christophe Paillart, and Roland Marquet
August 1992, Hospital practice (Office ed.),
Valérie Vivet-Boudou, and Catherine Isel, and Yazan El Safadi, and Redmond P Smyth, and Géraldine Laumond, and Christiane Moog, and Jean-Christophe Paillart, and Roland Marquet
January 2002, Current pharmaceutical design,
Valérie Vivet-Boudou, and Catherine Isel, and Yazan El Safadi, and Redmond P Smyth, and Géraldine Laumond, and Christiane Moog, and Jean-Christophe Paillart, and Roland Marquet
July 1997, Journal of medicinal chemistry,
Valérie Vivet-Boudou, and Catherine Isel, and Yazan El Safadi, and Redmond P Smyth, and Géraldine Laumond, and Christiane Moog, and Jean-Christophe Paillart, and Roland Marquet
August 1992, Hospital practice (Office ed.),
Valérie Vivet-Boudou, and Catherine Isel, and Yazan El Safadi, and Redmond P Smyth, and Géraldine Laumond, and Christiane Moog, and Jean-Christophe Paillart, and Roland Marquet
August 1992, Hospital practice (Office ed.),
Valérie Vivet-Boudou, and Catherine Isel, and Yazan El Safadi, and Redmond P Smyth, and Géraldine Laumond, and Christiane Moog, and Jean-Christophe Paillart, and Roland Marquet
June 2022, Toxicology letters,
Valérie Vivet-Boudou, and Catherine Isel, and Yazan El Safadi, and Redmond P Smyth, and Géraldine Laumond, and Christiane Moog, and Jean-Christophe Paillart, and Roland Marquet
October 1993, Antiviral research,
Valérie Vivet-Boudou, and Catherine Isel, and Yazan El Safadi, and Redmond P Smyth, and Géraldine Laumond, and Christiane Moog, and Jean-Christophe Paillart, and Roland Marquet
February 1999, Proceedings of the National Academy of Sciences of the United States of America,
Valérie Vivet-Boudou, and Catherine Isel, and Yazan El Safadi, and Redmond P Smyth, and Géraldine Laumond, and Christiane Moog, and Jean-Christophe Paillart, and Roland Marquet
September 1998, Antiviral chemistry & chemotherapy,
Copied contents to your clipboard!